This paper provides a comprehensive overview of Alzheimer's disease (AD), examining its symptoms, neuropathological features, diagnosis, and the two primary research directions aimed at treatment and prevention. The paper explores biological approaches — including the roles of cardiovascular risk factors, oxidative damage from free radicals, inflammation, and hormone therapy — alongside cognitive-behavioral approaches such as leisure activity, music therapy, and sensory stimulation. It also surveys FDA-approved pharmaceutical treatments, including cholinesterase inhibitors and other drug classes used to manage AD symptoms. The paper concludes that, given the complexity and variability of Alzheimer's presentation, a multifaceted treatment strategy combining biological and cognitive-behavioral methods offers the best hope for prevention and management.
The paper demonstrates effective synthesis across multiple primary sources. Rather than presenting each study in isolation, the author weaves findings from Cummings (2004), Rodgers (2002), and Vergese et al. (2003) into a coherent narrative about what is known, what is speculative, and what requires further research. This technique shows the writer's ability to evaluate the relative strength of evidence across sources.
The paper opens with an epidemiological framing of AD's public health significance, then moves through symptom progression and diagnosis before explaining the underlying neuropathology. The middle sections contrast biological research avenues (cardiovascular links, free radicals, inflammation, hormone therapy) with cognitive-behavioral ones (leisure activities, music and art therapy). The final sections catalog pharmaceutical options and call for a comprehensive, multifaceted treatment philosophy — providing a satisfying logical conclusion.
Alzheimer's disease currently affects more than four million Americans. It is characterized by the progressive degeneration of areas within the brain, resulting in cognitive and physical decline that will eventually lead to death. It is important to emphasize that Alzheimer's disease (AD) is not a normal part of aging. Although AD typically appears in those over sixty-five, it is a neurodegenerative disease, quite distinct from any aging-related cognitive decline. Because Alzheimer's is eventually fatal, and because the decline typical of an Alzheimer's patient is so devastating, much research is currently being done to investigate potential treatments. With the elderly population being the fastest-growing segment of North American society, Alzheimer's threatens to be an even greater health concern in future decades.
For patients exhibiting mild cognitive impairment, research is being done on ways to slow the disease's progression. The two main thrusts of Alzheimer's research are biological — which seeks to determine organic, systemic contributing factors to the disease — and cognitive-behavioral — which examines whether the disease can be held at bay by engaging the brain in novel functions. Pharmaceutically, there are a few drugs approved for the treatment of Alzheimer's. These drugs only postpone the dementia-related declines, however; they do not offer any cure.
The most common symptom of Alzheimer's disease is a progressive dementia. The symptoms are mild at first, with the patient experiencing impaired memory function, inattention, and difficulty performing everyday tasks. Because symptoms are initially mild, AD is frequently mistaken for normal decrements associated with aging. The ongoing brain damage that is occurring, however, leads to more severe symptoms. The AD patient will progress to a moderate dementia with — frequently — altered personality, difficulty with speaking or comprehension, and trouble moving. As the disease progresses, it becomes impossible for the Alzheimer's patient to be cared for at home, and the patient must enter a care facility. Eventually, the AD patient will become incontinent, unable to feed him- or herself, and will ultimately die. This progression from mild to moderate to severe takes, on average, seven years, but may take as long as fifteen or twenty.
The diagnosis of Alzheimer's is a diagnosis of exclusion. Other causes of similar symptoms must be ruled out, such as vascular insult, malnutrition, or adverse drug reactions. Autopsy is the only way to confirm diagnosis, by examining the brain damage that is characteristic of AD progression. One promising development in the area of Alzheimer's diagnosis is the use of the "Pittsburgh molecule." This process involves tagging a molecule that will bind with the amyloid plaques in the Alzheimer's patient's brain, allowing them to be detected with a brain scan.
In this test, patients are injected with a tiny amount of a harmless, radioactive molecule called Pittsburgh Compound B (PIB). PIB binds to protein aggregates called amyloid plaques that exist in the brains of those with Alzheimer's. The radioactive molecule can then be detected with a positron-emission tomography (PET) brain scan (Pilcher, 2004).
The most characteristic aspects of an AD patient's brain are neurofibrillary tangles and amyloid plaques. The plaques that form in the brains of AD patients are composed of a protein called beta-amyloid, which is formed from a precursor known as amyloid precursor protein (APP). These protein plaques are found predominantly in the brain's hippocampus, which is responsible for converting short-term memory into long-term memory. "In AD, plaques develop in the hippocampus, a structure deep in the brain that helps to encode memories, and in other areas of the cerebral cortex that are used in thinking and making decisions" (Rodgers, 2002, p. 22).
The other characteristic neuropathological feature of Alzheimer's is the formation of neurofibrillary tangles. These tangles involve another protein, tau. "In AD, tau is changed chemically. It begins to pair with other threads of tau and they become tangled up together. When this happens, the microtubules disintegrate" (Rodgers, 2002, p. 25). Although plaques and tangles may be present in a normal brain to a limited extent, in AD they overwhelm the neurons and impair their ability to function normally. "This hypothesized amyloid cascade underlies attempts to modify the onset and course of Alzheimer's disease through identification of antiamyloid agents, antioxidants, [and] anti-inflammatory drugs" (Cummings, 2004). It is normal for the human brain to change over time as a result of aging; however, Alzheimer's represents a decline that results from disease, not normal progression.
No one is certain what causes Alzheimer's, although it is becoming apparent that AD is, at least in part, related to a genetic predisposition. Other modifiable risk factors are also being investigated. Some ongoing research into Alzheimer's takes a biological approach aimed at mitigating the formation of protein conglomerations and preserving normal functioning for as long as possible.
Appropriate treatment options for Alzheimer's are hindered by a lack of definitive knowledge about the causes of the disease. "Although the prevention of dementia has emerged as a major public health priority, there is a paucity of potential preventive strategies. Identifying protective factors is essential to the formulation of effective interventions for dementia" (Vergese, 2003).
Alzheimer's disease is characterized by a variety of symptoms, causal theories, and patient demographic factors. As such, there are a wide range of treatment theories and approaches, with varying degrees of scientific evidence to support them. Since it is only within the last few decades that the full magnitude of AD in society has become clearer, much more scientifically valid research remains to be done.
Since the presentation of Alzheimer's is so varied, appropriate treatment responses must include both biological and cognitive-behavioral approaches. Only with a multifaceted treatment approach can one hope to maximize prevention and management of this disease.
Always verify citation format against your institution’s current style guide requirements.